#Israel #Petach Tikva #Medison #Shay Tamari #Tali Mirsky

Medison Expands Global Leadership Team

Medison, a pioneering force in global biotech commercialization, is making strategic moves to enhance its global leadership team. The company recently announced key appointments that promise to bolster its mission of delivering breakthrough therapies to underserved markets.

New Leadership Roles

Shay Tamari has joined Medison as the Chief Business Officer. With more than 20 years of experience in the pharmaceutical sector, including a significant tenure at Pfizer, Shay brings a wealth of knowledge and expertise to the table. His role will be crucial in driving Medison’s global corporate development strategy, focusing on identifying long-term growth opportunities and fostering strategic partnerships that will enhance the reach of Medison's unique platform.

Tali Mirsky, who has been appointed as Chief Legal and Compliance Officer, brings over 25 years of legal and compliance experience. Her background includes pivotal roles in both private and publicly traded companies, most recently at NICE. Tali’s insights into corporate governance, risk management, and compliance will be instrumental as Medison continues to expand globally, ensuring the company upholds the highest standards of ethical conduct while navigating a complex international landscape.

Strengthening Global Operations

Medison's unique platform is designed to help biotech firms efficiently plan, optimize, and launch their innovative therapies globally. The company’s approach leverages an end-to-end, centralized model that resembles an affiliate system, enabling seamless collaboration between various partners. As Medison aims to improve its operational capacities and deepen collaborations with biotech companies worldwide, these leadership appointments represent its commitment to cultivating a robust leadership structure.

During the announcement, Gil Gurfinkel, CEO of Medison, expressed confidence in the new appointments, stating, “The breadth of experience that Shay and Tali bring will be vital as we scale our operations and strive to provide breakthrough therapies to patients across the globe.”

A Vision for Global Access

The appointment of Shay and Tali underscores Medison's strategic focus on redefining biotech commercialization in a way that makes innovative therapies accessible to patients in regions where access has often been limited. The company's commitment to this mission has been echoed by its founder, Meir Jakobsohn, who remarked, “We are dedicated to ensuring that patients with rare and severe diseases have the opportunity for a better life, regardless of their location.”

Both Shay and Tali emphasized their enthusiasm for joining Medison at such a critical juncture. Shay noted, “Medison’s approach to global biotech commercialization is revolutionary and much needed. I look forward to enhancing our partnerships and facilitating greater access to vital therapies.” Tali added, “I am proud to be part of Medison’s journey in transforming global biotech commercialization, and I am dedicated to preserving the integrity and compliance necessary for sustainable growth.”

Building a Global Future

As Medison fortifies its leadership team with these strategic appointments, it prepares itself for the challenges ahead in the biotech landscape. By empowering its partners to bring breakthrough therapies to patients more effectively, Medison is not just focusing on expanding its business but is also dedicated to making a palpable impact on healthcare accessibility globally.

The ongoing efforts of Medison illustrate a profound belief that every patient deserves an equal opportunity for a fulfilling life, a vision that the company is resolutely translating into reality through its innovative models and impactful partnerships. The future of biotech commercialization is here, and with leaders like Shay Tamari and Tali Mirsky on board, Medison is well-prepared to navigate it.